Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy

Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER